Literature DB >> 20466372

Reduction in serum apoB is associated with reduced inflammation and insulin resistance in post-menopausal women: A MONET study.

May Faraj1, Marie-Eve Lavoie, Lyne Messier, Jean-Philippe Bastard, Denis Prud'homme.   

Abstract

OBJECTIVE: Large inter-individual variations exist in changes in inflammation and insulin resistance (IR) in response to hypocaloric-interventions in obese subjects that are not explained by weight-loss per se. We identified the number of serum apoB-lipoproteins (serum apoB) as the primary predictor of inflammatory markers in post-menopausal overweight/obese women. As apoB-lipoproteins are related to inflammation and inflammation promotes IR, we hypothesized that the reduction in inflammation and IR following hypocaloric-interventions is associated with the reduction in serum apoB. METHODS/
RESULTS: After a 6-month hypocaloric-dietary-intervention in 56 overweight/obese post-menopausal women, there was a significant reduction in weight, total, subcutaneous abdominal and visceral abdominal fat mass, apoB, Lp(a), hsCRP, orosomucoid, haptoglobin and IR (increased M(clamp)) and an increase in LDL-C/apoB ratio. In regression analysis, % change in apoB was the primary predictor of % changes in hsCRP (R(2)=0.22), orosomucoid (R(2)=0.35), haptoglobin (R(2)=0.43) and M(clamp) (R(2)=0.17). When the study population was split around baseline median apoB (0.97g/L), women who were above median apoB (N=27) had significant reduction in apoB (-17%), hsCRP (-24%), orosomucoid (-8%), haptoglobin (-18%) and IR (M(clamp) +14%). On the other hand, women below median apoB (N=29) had no significant changes in these parameters despite equivalent reduction in weight and fat depots in the two groups.
CONCLUSION: Reduction in apoB associated strongly and independently with the reduction in inflammatory markers and IR following a hypocaloric-diet in overweight/obese women. We hypothesize that the elevated apoB phenotype may be key therapeutic target to reduce obesity-associated inflammation and IR maximally by hypocaloric-dietary-interventions. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466372     DOI: 10.1016/j.atherosclerosis.2010.04.012

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Nontraditional risk factors for cardiovascular disease and visceral adiposity index among different body size phenotypes.

Authors:  T Du; J Zhang; G Yuan; M Zhang; X Zhou; Z Liu; X Sun; X Yu
Journal:  Nutr Metab Cardiovasc Dis       Date:  2014-08-07       Impact factor: 4.222

Review 2.  The "New Deadly Quartet" for cardiovascular disease in the 21st century: obesity, metabolic syndrome, inflammation and climate change: how does statin therapy fit into this equation?

Authors:  Michael Clearfield; Melissa Pearce; Yasmin Nibbe; David Crotty; Alesia Wagner
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

3.  Low density lipoprotein delays clearance of triglyceride-rich lipoprotein by human subcutaneous adipose tissue.

Authors:  Simon Bissonnette; Huda Salem; Hanny Wassef; Nathalie Saint-Pierre; Annie Tardif; Alexis Baass; Robert Dufour; May Faraj
Journal:  J Lipid Res       Date:  2013-02-17       Impact factor: 5.922

4.  Association between serum apolipoprotein B and atrial fibrillation: a case-control study.

Authors:  Xia Zhong; Huachen Jiao; Dongsheng Zhao; Jing Teng
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

5.  Case-Control Study to Investigate the Association Between Serum Apolipoprotein B/A1 Ratio and Atrial Fibrillation by Sex in 920 Patients from China.

Authors:  Xia Zhong; Huachen Jiao; Dongsheng Zhao; Jing Teng; Mengqi Yang
Journal:  Med Sci Monit       Date:  2022-05-14

Review 6.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

7.  Plasma IL-1Ra: linking hyperapoB to risk factors for type 2 diabetes independent of obesity in humans.

Authors:  S Bissonnette; N Saint-Pierre; V Lamantia; Y Cyr; H Wassef; M Faraj
Journal:  Nutr Diabetes       Date:  2015-09-28       Impact factor: 5.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.